CervoMed Names William Elder As Chief Financial Officer, Effective June 1, 2024
CervoMed Names William Elder As Chief Financial Officer, Effective June 1, 2024
CervoMed 任命 William Elder 爲首席財務官，自 2024 年 6 月 1 日起生效
CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced the appointment of William (Bill) Elder as Chief Financial Officer, effective June 1, 2024. Mr. Elder will continue to serve as General Counsel and Corporate Secretary. He will succeed William Tanner who has served as Chief Financial Officer to CervoMed and its predecessor, EIP Pharma, since September 2022. Mr. Tanner will continue as a consultant to CervoMed following the transition.
CervoMed公司（納斯達克：CRVO）是一家專注於開發治療與年齡相關的神經系統疾病的臨床階段公司，今日宣佈任命威廉（比爾）·艾爾德爲首席財務官，任命將於2024年6月1日生效。艾爾德先生將繼續擔任總法律顧問和公司秘書職務。他將取代威廉·坦納，後者自2022年9月以來一直擔任CervoMed及其前身EIP Pharma的首席財務官。轉型後，坦納先生將繼續擔任CervoMed的顧問。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。